Abstract
In this article, the synergistic effects of WP 631 and epothilone B (Epo B) combination in human ovarian cancer cells (SKOV-3) cells are investigated and the reasons for the exact mechanisms of action of both drugs co-administered are explained. Compared with single drugs, the combination treatment significantly enhances apoptosis as confirmed by increases in caspases (-8, -9, -3) activity, ROS level and DNA damage and decreases in mitochondrial membrane potential. The combination of the compounds activated both caspase - 8 and -9, indicates that both pathways of apoptosis, extrinsic (induced by the effect of Epo B) and intrinsic (triggered mainly by WP 631) participate in the proposed treatment. Thus, the results of this study strongly suggest a synergistic action of the combined treatment with WP 631 and Epo B in SKOV-3 cells death induction.
Keywords: Apoptosis, epothilone B, ovarian cancer, synergism, WP 631.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Caspases and ROS - Dependent Mechanism of Action Mediated by Combination of WP 631 and Epothilone B
Volume: 14 Issue: 9
Author(s): Aneta Rogalska, Barbara Bukowska and Agnieszka Marczak
Affiliation:
Keywords: Apoptosis, epothilone B, ovarian cancer, synergism, WP 631.
Abstract: In this article, the synergistic effects of WP 631 and epothilone B (Epo B) combination in human ovarian cancer cells (SKOV-3) cells are investigated and the reasons for the exact mechanisms of action of both drugs co-administered are explained. Compared with single drugs, the combination treatment significantly enhances apoptosis as confirmed by increases in caspases (-8, -9, -3) activity, ROS level and DNA damage and decreases in mitochondrial membrane potential. The combination of the compounds activated both caspase - 8 and -9, indicates that both pathways of apoptosis, extrinsic (induced by the effect of Epo B) and intrinsic (triggered mainly by WP 631) participate in the proposed treatment. Thus, the results of this study strongly suggest a synergistic action of the combined treatment with WP 631 and Epo B in SKOV-3 cells death induction.
Export Options
About this article
Cite this article as:
Rogalska Aneta, Bukowska Barbara and Marczak Agnieszka, Caspases and ROS - Dependent Mechanism of Action Mediated by Combination of WP 631 and Epothilone B, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (9) . https://dx.doi.org/10.2174/1871520614666140608150807
DOI https://dx.doi.org/10.2174/1871520614666140608150807 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics Outcome Measures Following Sonodynamic Photodynamic Therapy – A Case Series
Current Drug Therapy Bioengineering RNA Silencing Across the Life Kingdoms
Recent Patents on Biotechnology Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Current Pharmaceutical Design Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Synthesis and Anticancer Activities of New Benzothiadiazinyl Hydrazinecarboxamides and Anilino[1,2,4]triazolo[1,5-b][1,2,4]thiadiazine 5,5-diones
Medicinal Chemistry Synthetic Hammerhead Ribozymes as Therapeutic Tools to Control Disease Genes
Current Gene Therapy Targeting Gene Therapy for Prostate Cancer
Current Pharmaceutical Design Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?
Current Pharmacogenomics Osteoinductive Small Molecules: Growth Factor Alternatives for Bone Tissue Engineering
Current Pharmaceutical Design Relevance of Protein Isoforms in Proteomic Studies
Current Proteomics Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets Recent Advances in Targeting Nuclear Molecular Imaging Driven by Tetrazine Bioorthogonal Chemistry
Current Medicinal Chemistry Radioprotective Gene Therapy
Current Gene Therapy Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Advances in Drug Safety
Current Pharmaceutical Design The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives
Current Medicinal Chemistry Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Current Drug Targets Particle Sorting in Microfluidic Systems
Micro and Nanosystems Challenges and Successes Using Nanomedicines for Aerosol Delivery to the Airways
Current Gene Therapy